Zyprexa OD Tablets 5 mg (Olanzapine)

Adult dose

The therapeutic dose of this medicine should be adjusted according to the patient's clinical condition. Dose increases above the usual recommended daily dose of 10 mg are recommended only after an appropriate clinical evaluation. 1. Adults 1) Schizophrenia (1) The recommended initial dose is 5∼10 mg of olanzapine once daily. (2) Maintenance treatment: Although it is difficult to give a definitive answer regarding how long treatment with this medicine should continue, its efficacy was demonstrated in a placebo-controlled study in which patients with schizophrenia whose symptoms had stabilized after taking this medicine for approximately 8 weeks received maintenance treatment at a dose of 10∼20 mg daily for 8 months. The need for maintenance treatment at an appropriate dose should be assessed periodically. 2) Bipolar disorder (1) Treatment of manic and mixed episodes associated with bipolar I disorder The initial dose is 15 mg of this medicine once daily as monotherapy, or 10 mg once daily as adjunctive therapy with lithium or valproate. (2) Prevention of recurrence in bipolar disorder The recommended initial dose is 10 mg once daily. In patients who have received this medicine to treat mania, continue the same dose to prevent recurrence. If a new manic, mixed, or depressive episode occurs, treatment with this medicine should be continued, together with adjunctive therapy to treat mood symptoms as clinically indicated (optimizing the required doses). 3) For schizophrenia, treatment of manic and mixed episodes associated with bipolar I disorder, and prevention of recurrence in bipolar disorder, the daily dose may be adjusted within the range of 5 mg to 20 mg based on clinical condition. Doses above the recommended initial dose are recommended only after an appropriate clinical evaluation and should generally be increased at intervals of at least 24 hours. If treatment with this medicine is discontinued, the dose should be reduced gradually and carefully. 4) Acute treatment of depressive episodes associated with bipolar I disorder Start treatment with olanzapine 5 mg once daily, then increase to 10 mg once daily. Administer this medicine at bedtime and adjust the dose as appropriate according to age and symptoms; the daily dose should not exceed 20 mg. Food does not affect drug absorption, so this medicine may be taken with or without food. 2. Administration in special populations 1) Elderly patients Starting at a dose of 5 mg or less once daily may be considered when there is sufficient evidence based on clinical factors. 2) Patients with renal or hepatic impairment A low initial dose (5 mg) should be considered. In moderate hepatic impairment (cirrhosis, Child-Pugh class A or B), the initial dose is 5 mg and should be increased cautiously. 3) Patients with a combination of factors that delay the metabolism of this medicine (female sex, older age, and nonsmoking status) may also be started at a low dose. 3. Precautions (for orally disintegrating tablets only) This medicine is fragile. Remove it from the outer package by peeling back the metal foil on the back of the blister to open it. Do not push the tablet through the metal foil when opening the blister. Immediately after opening the blister, remove the tablet with dry hands and place it directly in the mouth. The tablet rapidly disintegrates in saliva and may be swallowed with or without a drink.

This medication affects the nervous system and can rarely cause serious side effects such as neuroleptic malignant syndrome, which can be life-threatening. If symptoms occur, discontinue use immediately and consult a doctor. It is not recommended for the treatment of psychosis or behavioral disorders related to dementia, as this patient group may have increased mortality and risk of cerebrovascular disorders. Prolonged use may lead to the emergence of tardive dyskinesia; if symptoms occur, dosage adjustment or cessation should be considered. Initial treatment may take time for symptom improvement, so close observation of the patient's condition is necessary. In patients with diabetes or high-risk groups, there may be a worsening in blood sugar control, necessitating regular monitoring of blood sugar and weight. Abruptly discontinuing this medication may result in withdrawal symptoms such as insomnia, anxiety, and tremors; therefore, it is safer to taper the dosage gradually. Caution should be exercised when prescribing to patients with specific liver diseases, seizure history, cardiovascular diseases, elderly patients, pregnant women, and nursing mothers, and consultation with a physician is advised. This medication may cause drowsiness and dizziness, so caution is needed while driving or operating hazardous machinery. There may be drug interactions; inform your doctor of any medications you are taking, especially since co-administration with epinephrine is prohibited. Overdose may result in serious heart problems or loss of consciousness, necessitating immediate medical intervention. Keep out of reach of children and store in a cool place away from direct sunlight and moisture.

• High fever
• muscle rigidity
• changes in mental state
• irregular pulse
• fluctuations in blood pressure
• tachycardia
• sweating
• arrhythmia
• elevated creatine phosphokinase
• myoglobinuria

This medication should be stored in a special container to protect it from light and air, avoiding humid areas and keeping it in a cool temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for an extended period.

Appearance

Light yellow oval oral disintegrating tablet

Package unit

28 tablets (7 tablets × 4)/PTP